Aggrenox® versus other pharmacotherapy in preventing recurrent stroke

Author： Redman Andrea R   Ryan Gina J  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.1, 2004-01, pp. : 117-123

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aspirin: first choice for preventing recurrent stroke?

By  

Inpharma, Vol. 1, Iss. 1356, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Pharmacotherapy of recurrent respiratory papillomatosis

By Kimberlin David W  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 8, 2002-08 ,pp. : 1091-1099

Informa Healthcare

Access to resources Recommend Favorite

Pharmacotherapy for the Secondary Prevention of Stroke

By Toyoda Kazunori  

Drugs, Vol. 69, Iss. 6, 2009-01 ,pp. : 633-647

Adis International

Access to resources Recommend Favorite

Economic Assessment of the Secondary Prevention of Ischaemic Stroke with Dipyridamole plus Aspirin (Aggrenox ® /Asasantin ® ) in France

By Jean-Pierre Marissal   Bernard Selke  

PharmacoEconomics, Vol. 22, Iss. 10, 2004-01 ,pp. : 661-670

Adis International

Access to resources Recommend Favorite

Eprosartan protects against recurrent stroke

By  

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite